Novartis
Diovan trials may have been run by Novartis staff
May 29, 2013Research and Development, Sales and Marketing Diovan, Novartis
Several post-marketing clinical trials of the blockbuster blood pressure drug Diovan may have been run by employees of the drug’s …
‘Solid’ start for Novartis
April 30, 2013Sales and Marketing Novartis, Q1, sales
Novartis’ sales of pharma products were unchanged in the first quarter of 2013 at $7.9 billion, with pricing flat, the …
EU approval for Ilaris
March 4, 2013Sales and Marketing Ilaris, Novartis
Novartis’ Ilaris has become the first biologic approved by the European Commission to treat patients suffering acute gouty arthritis attacks …
Vasella forgoes golden handshake after furore
February 19, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Vasella
Novartis has backed down over plans to pay outgoing chairman Dr Daniel Vasella a ‘golden handshake’ worth $77 million (72 …
Another approval for Novartis’ everolimus
February 18, 2013Sales and Marketing Certican, Novartis, Zortress, everolimus
Novartis has gained US approval for its drug Zortress (everolimus) to prevent liver transplant rejection.Zotress is already used to prevent …
Novartis’ Nebraska OTC plant still troubles company
February 11, 2013Manufacturing and Production Novartis, OTC
Novartis has been forced to recall various over-the-counter (OTC) medicines made at its plant in Lincoln, Nebraska, after discovering failures …
Facility of the year: 2013 winners announced
February 4, 2013Manufacturing and Production Biogen, MedImmune, Merck, Novartis, Roche
Three US and three European manufacturing plants have been selected as category winners for the annual Facility of the Year …
NICE recommends two cystic fibrosis treatments
January 25, 2013Sales and Marketing Colobreath, Forest Labs, Novartis, Tobi Podhaler, cystic fibrosis
NICE has given final recommendation to two new inhalers for cystic fibrosis (CF) patients.Forest Lab’s Colobreath (colistimethate sodium) and Novartis’ …
Novartis’ 2012 results flat
January 24, 2013Sales and Marketing Bexsero, Jakavi, Novartis, generics, results
Generic competition has put a dent in Novartis’ financial results for 2012, with net sales down 3% year on year …
Jörg Reinhardt to leave Bayer for Novartis
January 24, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Novartis, Reinhardt
The chairman of the Board and member of the Bayer executive council Dr Jörg Reinhard is stepping down from his …
EU approval for meningitis vaccine
January 23, 2013Sales and Marketing Bexsero, CHMP, Novartis, meningitis
European regulators have approved Novartis’ Bexsero, making it the first broad coverage vaccine to target the leading cause of meningitis. …
Novartis eye drug nears approval
January 21, 2013Sales and Marketing AMD, CHMP, Jetria, Novartis
Novartis’ eye drug Jetrea has been given a positive opinion by the CHMP, pushing it to the brink of approval. …
Eisai and Novartis part ways
January 8, 2013Sales and Marketing COPD, Eisai, Novartis, Onbrez, Spiriva
Novartis and Eisai have abandoned their co-promotion agreement for three of Novartis’ chronic obstructive pulmonary disease treatments. The move follows …
New price and data changes NICE view on Lucentis
January 4, 2013Sales and Marketing Bayer, Eylea, Lucentis, NICE, Novartis
A new lower price and new data analysis has persuaded NICE to recommend Lucentis for patients with diabetic macular oedema …
Signifor approved in US
December 17, 2012Sales and Marketing Cushing's, Novartis, Signifor
Novartis’ injection Signifor has been approved by the FDA to treat Cushing’s disease, a rare but serious endocrine disorder affecting …
Latest content
FibroFind appoints Lee Borthwick as CEO
